Company news
Vtv Therapeutics Inc. (NASDAQ:VTVT) news
Vtv Therapeutics Inc. news releases on 6ix. Latest, Oct 6, 2026: vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes…
Press releases & updates
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
October 5, 2026
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
October 6, 2026
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
October 4, 2026
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
October 5, 2026
vTv Therapeutics to Participate in September Investor Conferences
September 2, 2026
VTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2026
VTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
June 3, 2026
VTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
vTv Therapeutics to Participate in Upcoming May Investor Conferences
May 7, 2026
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
March 15, 2026
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 9, 2026
vTv Therapeutics to Participate in Upcoming Investor Conferences
February 13, 2026
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
February 2, 2026
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
December 18, 2025
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 6, 2025
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
October 9, 2025
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
September 15, 2025
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2025
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
September 2, 2025
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 12, 2025
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
August 11, 2025
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
August 7, 2025
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
June 11, 2025
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
May 19, 2025
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
May 15, 2025
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
May 15, 2025
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
March 20, 2025
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
March 17, 2025
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
December 8, 2024
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
December 1, 2024
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
November 11, 2024
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
August 7, 2024
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
July 25, 2024
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
June 23, 2024
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
May 8, 2024
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
March 12, 2024
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
March 3, 2024
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
February 29, 2024
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
February 27, 2024
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
November 8, 2023
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
November 7, 2023
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
November 1, 2023
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
October 31, 2023
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
August 10, 2023
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
June 15, 2023
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
May 23, 2023
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
May 10, 2023
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
March 5, 2023